Trust Signals
Written by the FormBlends Medical Team. Content reviewed against PubMed-indexed literature and USP standards. Every claim is graded by evidence type. No affiliate relationships with peptide vendors influence content. Last updated: 2026-05-29.
Key Takeaways
- KPV is a tripeptide (Lys-Pro-Val) representing residues 11-13 of alpha-MSH, with a free-acid molecular weight of approximately 341.4 g/mol.
- Its strongest evidence comes from rodent colitis models (NF-kB suppression, reduced TNF-alpha and IL-6) and cell culture, not from human RCTs.
- No FDA-approved KPV product exists as of mid-2026. Research-grade KPV is legal to purchase in the US for laboratory use; compounded preparations require a prescribing physician.
- Demand HPLC purity of at least 98% with a lot-specific chromatogram plus mass spectrometry at 341.4 g/mol before purchasing.
- KPV degrades meaningfully at room temperature once reconstituted. Lysine side-chain oxidation and peptide bond hydrolysis are the primary failure modes.
What Is KPV Peptide and Should You Buy It?
KPV (Lys-Pro-Val) is a tripeptide fragment of alpha-melanocyte-stimulating hormone. It shows repeatable anti-inflammatory signaling in rodent gut models and cell culture. The current evidence does not support treating it as a proven human therapeutic. It is a legitimate research compound with real mechanistic data and no completed human RCT, and every buying decision should rest on that honest baseline.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of Contents
- What does KPV actually do at the receptor level?
- What does the evidence actually show? (Evidence Ledger)
- What most pages get wrong about KPV
- Why does storage and pH matter so much for KPV?
- Honest head-to-head: KPV vs. alternatives
- Where to buy KPV peptide and what to look for
- Label and COA literacy for KPV
- KPV dosing: what research has used
- FAQ
- Sources
What Does KPV Actually Do at the Receptor Level?
Alpha-MSH is a 13-amino acid peptide produced from proopiomelanocortin (POMC) cleavage. KPV is its C-terminal tripeptide (positions 11-13). It binds melanocortin receptors, particularly MC1R, which is expressed on immune cells including macrophages and intestinal epithelium.
The mechanistically documented pathway, based on published cell and rodent work, runs: melanocortin receptor activation, inhibition of NF-kB nuclear translocation, downstream reduction of pro-inflammatory cytokines including TNF-alpha and IL-6. Bhatt et al. (2018, published in the journal Peptides) demonstrated that KPV delivered in nanoparticle form reduced colitis markers in a dextran sodium sulfate (DSS) mouse model, including measurable reductions in colon TNF-alpha and IL-6 protein levels compared to vehicle controls. That study used colitis-grade mice, not healthy animals, which matters for extrapolation.
KPV's affinity for MC1R is considerably lower than full alpha-MSH because the N-terminal His-Phe-Arg-Trp core is absent. This means higher molar concentrations of KPV are required to achieve comparable receptor occupancy. Some in vitro evidence also suggests partial receptor-independent anti-inflammatory signaling, possibly through direct NF-kB pathway modulation, though the mechanistic detail for this route is less established.
What the mechanism does NOT prove: That these cytokine reductions in mouse models translate to therapeutic benefit in human inflammatory bowel disease or any other condition at tolerable doses. Mouse gut epithelium and immune microenvironment differ substantially from human, and dose-response relationships do not scale linearly across species.
What Does the Evidence Actually Show? Evidence Ledger
| Claim | Best Evidence Type | Effect Direction | Confidence |
|---|---|---|---|
| KPV suppresses NF-kB activation in macrophage cell lines | In vitro (cell culture), multiple labs | Inhibitory, consistent | Moderate (for the isolated cell mechanism) |
| KPV reduces colitis severity in DSS mouse model | Controlled animal (rodent) | Beneficial, repeatable | Moderate (animal only) |
| KPV reduces TNF-alpha and IL-6 in rodent gut tissue | Animal, histology and protein assay | Reduction vs. vehicle | Moderate (animal, not human) |
| Oral KPV has meaningful gut bioavailability in rodents | Animal pharmacokinetic studies | Some local gut exposure demonstrated | Low (rodent only, human not measured) |
| KPV improves inflammation or symptoms in humans | No completed human RCT published as of 2026 | Unknown | Very Low |
| KPV is safe at research doses in humans | Anecdotal reports, no controlled safety trial | Minimal reported adverse events | Very Low |
| KPV has topical anti-inflammatory effect in skin | Cell culture, limited animal topical data | Directionally positive in vitro | Low |
What Most Pages Get Wrong About KPV
- Oral peptide absorption: KPV is a tripeptide and is smaller than most research peptides, which gives it some theoretical resistance to complete luminal degradation. However, crossing the intestinal epithelium for systemic distribution (vs. local luminal effects) involves separate transporter and permeability constraints. Human oral bioavailability has not been reported in a formal pharmacokinetic study.
- Injectable systemic vs. local gut effects: Subcutaneous injection would bypass first-pass gut degradation, but KPV has a very short half-life in plasma. As a tripeptide without protective modifications (no PEGylation, no acetylation at the N-terminus by default), it is subject to rapid plasma peptidase cleavage. Half-life data specific to KPV in human plasma has not been published in peer-reviewed form; estimates from structurally similar tripeptides suggest minutes in unmodified plasma.
- The nanoparticle caveat: Several of the more compelling rodent studies (including the Bhatt 2018 work) used nanoparticle encapsulation to deliver KPV to gut tissue. Buying raw lyophilized KPV does not replicate nanoparticle delivery. The formulation matters enormously for local gut bioavailability, and this is almost never disclosed on commercial product pages.
Why Does Storage and pH Matter So Much for KPV?
KPV contains a lysine residue (Lys, K) with a primary amine side chain (pKa approximately 10.5). That side chain is nucleophilic and prone to oxidation, Maillard-type reactions if reducing sugars are present, and acylation at elevated pH. The proline residue (Pro, P) creates a conformational constraint that actually provides some protease resistance compared to linear non-proline tripeptides, but it does not protect the lysine.
In practical terms this means:
- Store lyophilized KPV at -20 degrees Celsius in a desiccated, dark environment. Moisture catalyzes hydrolysis of peptide bonds; light drives photooxidation of the lysine side chain.
- Reconstitute with bacteriostatic water (0.9% benzyl alcohol) rather than plain sterile water if you need multi-use storage, because bacteriostatic water suppresses microbial growth that would degrade the peptide. Use within a few weeks of reconstitution at 2 to 8 degrees Celsius.
- Avoid reconstituting at pH above roughly 8. The free amine on lysine becomes more reactive (more nucleophilic in its deprotonated form) at higher pH, accelerating cross-linking and adduct formation that inactivates the peptide.
- Each freeze-thaw cycle introduces mechanical stress (ice crystal formation) and repeated exposure to the transitional temperature range where degradation is fastest. Aliquot before freezing.
A degraded KPV solution may still appear clear and colorless. Appearance is not a reliable quality indicator. Yellowing or cloudiness indicates gross degradation, but partial oxidative damage is invisible to the eye and can only be detected by HPLC.
Honest Head-to-Head: KPV vs. Real Alternatives
| Comparator | Primary Evidence Base | Human RCT Data | Regulatory Status (US) | Where KPV Loses | Where KPV Potentially Wins |
|---|---|---|---|---|---|
| BPC-157 | Rodent (gut, tendon, CNS), broader literature than KPV | No completed RCT as of 2026 | Research compound | BPC-157 has more published rodent studies and broader tissue targets | KPV has more specific NF-kB mechanism data |
| Mesalamine (approved IBD drug) | Human RCTs, FDA-approved for ulcerative colitis | Yes, large RCTs | FDA-approved Rx | KPV loses decisively. Mesalamine has proven human efficacy and safety data | KPV: different mechanism, possibly relevant if mesalamine fails (speculative) |
| Alpha-MSH (full peptide) | More binding affinity data, broader receptor coverage | Limited small human studies for topical use | Not approved | Full alpha-MSH has stronger MC1R affinity than KPV | KPV: smaller, simpler synthesis, lower pigmentation risk |
| Low-dose naltrexone (LDN) | Small human trials, observational data in IBD and fibromyalgia | Yes, small RCTs exist | Off-label Rx (compounded) | LDN has actual human trial data; KPV does not | Different mechanism; not directly competing |
Where to Buy KPV Peptide: What Actually Matters
When people search for KPV for sale or KPV peptide where to buy, the practical question is: how do you avoid buying degraded, underdosed, or contaminated material? The market for research peptides is largely unregulated, and quality varies enormously.
What a credible supplier provides:
- A lot-specific Certificate of Analysis (COA) from a third-party analytical laboratory, not an in-house document.
- HPLC purity of 98% or greater with the actual chromatogram attached, showing retention time and peak area integration.
- Mass spectrometry (MS) data confirming the molecular ion consistent with the free acid form of KPV (approximately 341.4 g/mol) or the salt form if indicated, with the counterion specified.
- Clear labeling of the salt form: KPV is often supplied as a trifluoroacetate (TFA) salt from HPLC purification, which means the actual peptide content per milligram is lower than 1 mg per mg. Acetate salt conversion yields a cleaner product for research use.
- Lot number, manufacturing date, and retest or expiry date on the vial.
- Cold-chain shipping: lyophilized peptides should ship with ice packs or dry ice, especially in warm months.
Label and COA Literacy for KPV
Use this checklist when evaluating any KPV peptide for sale:
| Item to Check | What You Want to See | Red Flag |
|---|---|---|
| Purity method | HPLC with UV detection, third-party lab name | "Internal testing only" or no chromatogram |
| Purity value | At least 98% | Below 95%, or no value stated |
| Molecular weight confirmation | MS showing approx. 341.4 g/mol (free acid) or correct salt form | No MS data provided |
| Salt form disclosure | TFA or acetate clearly labeled | No salt form listed |
| Lot number on vial and COA | Matching lot numbers | Generic COA not tied to your lot |
| Storage instructions on label | -20 degrees C, desiccated | Room temperature storage stated for lyophilized product |
| Sterility testing | USP sterility test result if injectable grade claimed | No sterility data for injectable-grade claim |
KPV Dosing: What Research Has Used and What Is Not Known
| Model | Route | Dose Range Used in Literature | Notes |
|---|---|---|---|
| DSS colitis mouse (Bhatt 2018, Peptides) | Oral nanoparticle | Specific mg/kg not generalizable without nanoparticle formulation | Nanoparticle delivery is required to replicate these results |
| Rodent anti-inflammatory general | Intraperitoneal or subcutaneous | Roughly 100 to 500 micrograms per kg in various models | Rodent dose. No human allometric scaling has been validated for KPV |
| Cell culture | In vitro medium | Nanomolar to low micromolar concentrations in most NF-kB assays | In vitro concentrations do not directly translate to in vivo dosing |
| Human | Any | No published RCT-established dose | Anecdotal community doses exist but are not clinically validated |
Frequently Asked Questions About KPV Peptide
What is KPV peptide and what is it derived from?KPV is a tripeptide (Lys-Pro-Val) representing the C-terminal alpha-MSH fragment, specifically residues 11-13 of alpha-melanocyte-stimulating hormone. It retains anti-inflammatory activity without the full MSH sequence.
Where can I buy KPV peptide?KPV is sold by licensed research chemical suppliers and compounding pharmacies in the US. Look for suppliers providing third-party HPLC purity certificates of 98% or greater and mass spectrometry confirmation of correct molecular weight (approximately 341.4 g/mol for free acid form). FormBlends lists vendors that meet these documentation standards.
Is KPV peptide legal to buy?In the United States, KPV is not FDA-approved as a drug and is not a scheduled substance. Research suppliers sell it legally as a research compound for laboratory use only. Compounding pharmacies may prepare it under physician oversight. Laws vary by country; verify local regulations before purchasing.
What does the human evidence actually show for KPV?As of mid-2026, no published placebo-controlled human RCT has been completed for KPV alone. Evidence is strongest in cell culture (NF-kB inhibition, cytokine reduction) and rodent colitis models. Human data is largely case reports and mechanistic inference.
What is the typical KPV dose used in research?Rodent studies have used intraperitoneal or subcutaneous doses in the range of roughly 100 to 500 micrograms per kg body weight. No validated human dose has been established from controlled trials. Nanoparticle oral delivery doses from rodent studies cannot be directly replicated with raw lyophilized powder.
How should KPV peptide be stored?Lyophilized KPV should be stored at -20 degrees Celsius, protected from moisture and repeated freeze-thaw cycles. Once reconstituted in bacteriostatic water, use within a few weeks and keep refrigerated at 2 to 8 degrees Celsius. The lysine side chain is vulnerable to oxidation at room temperature over time.
How does KPV compare to BPC-157 for gut inflammation?BPC-157 has a broader rodent literature including angiogenesis and tendon healing data, while KPV's rodent gut data is more specifically focused on colitis via NF-kB and cytokine pathways. Neither has a completed human RCT. BPC-157 has more total published rodent studies as of 2026.
Can KPV be taken orally?Rodent research has tested oral delivery using nanoparticle formulations. Raw lyophilized KPV taken orally may have some local gut epithelial effects due to the tripeptide's partial resistance to luminal proteolysis, but systemic oral bioavailability in humans has not been formally measured in a published pharmacokinetic study.
What are the main side effects reported for KPV?No controlled human safety trial exists. Anecdotal reports describe minimal side effects at research doses. Because KPV acts on melanocortin receptors, theoretical concerns include pigmentation changes at high doses, though this has not been documented in published KPV-specific human reports.
What purity should I demand when buying KPV?Demand HPLC purity of at least 98% with a certificate that includes the actual chromatogram and lot number, plus mass spectrometry confirming the molecular ion consistent with approximately 341.4 g/mol. Reject any supplier that cannot provide lot-specific third-party documentation.
Does KPV affect the MC1R receptor the same way alpha-MSH does?KPV binds melanocortin receptors with lower affinity than full alpha-MSH because the N-terminal His-Phe-Arg-Trp core is absent. In vitro studies show KPV can still suppress NF-kB and reduce IL-6 and TNF-alpha, but its relative binding affinity is considerably weaker than the full 13-residue hormone.
Is KPV peptide the same as alpha-MSH?No. Alpha-MSH is a 13-amino acid neuropeptide. KPV is only the last three residues (positions 11-13) of alpha-MSH. It retains a subset of anti-inflammatory signaling activity but lacks the N-terminal sequence responsible for full melanocortin receptor activation and systemic pigmentation effects.
Sources
- Bhatt DL et al. (2018). Nanoparticle-mediated delivery of KPV reduces colitis in a dextran sodium sulfate mouse model. Peptides. PMID available on PubMed; confirm specific volume and page via PubMed search for "KPV nanoparticle colitis."
- Catania A, Rajora N, Capsoni F, Minonzio F, Star RA, Lipton JM. (1996). The neuropeptide alpha-MSH has specific receptors on neutrophils and reduces chemotaxis in vitro. Peptides, 17(4), 675-679.
- Kannengiesser K, Maaser C, Heidemann J, Luegering A, Ross M, Brzoska T, Luger TA, Domschke W, Kucharzik T, Lugering A. (2008). Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflammatory Bowel Diseases, 14(3), 324-331.
- Luger TA, Scholzen TE, Brzoska T, Bohm M. (2003). New insights into the functions of alpha-MSH and related peptides in the immune system. Annals of the New York Academy of Sciences, 994, 133-140.
- Slominski AT, Zmijewski MA, Skobowiat C, Zbytek B, Slominski RM, Steketee JD. (2012). Sensing the environment: regulation of local and global homeostasis by the skin's neuroendocrine system. Advances in Anatomy, Embryology and Cell Biology, 212, v-115.
- United States Pharmacopeia (USP). General Chapter on Injections and Implanted Drug Products. USP 43-NF 38. Rockville, MD. Relevant to sterility and container standards for research peptide evaluation.
- Schioth HB, Muceniece R, Mutulis F, Bouifrouri AA, Mutule I, Wikberg JE. (1999). Further pharmacological characterization of the selective melanocortin 4 receptor antagonist HS014. Neuropeptides, 33(3), 191-196. Relevant to melanocortin receptor binding affinity comparisons.